Status:
COMPLETED
Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
The Leukemia and Lymphoma Society
Conditions:
Chronic Lymphocytic Leukemia
Plasma Cell Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
This trial studies financial difficulty in participants with chronic lymphocytic leukemia and multiple myeloma. Assessment of financial difficulty may help to better understand the financial impact of...
Detailed Description
The primary and secondary objectives of the study: PRIMARY OBJECTIVES: I. To estimate the proportion of patients with multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) who report experienc...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- PATIENT ELIGIBILITY CRITERIA
- Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
- Patients' medical records must be available to the registering institution
- Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who:
- Are presently being treated with infused or orally-administered anticancer therapy, OR
- Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR
- Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment
- Not currently enrolled in a clinical trial in which drug is supplied by the study
- Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible
- Patients must be able to read and comprehend English or Spanish
- SITE ELIGIBILITY CRITERIA
- Intent to complete the A231602CD Site of Care Survey
- Access to patient medical records: Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data)
- Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site to be able to conduct the informed consent discussion in Spanish
Exclusion
Key Trial Info
Start Date :
May 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
521 Patients enrolled
Trial Details
Trial ID
NCT03870633
Start Date
May 14 2019
End Date
May 1 2023
Last Update
January 17 2025
Active Locations (116)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States, 99508
2
Anchorage Oncology Centre
Anchorage, Alaska, United States, 99508
3
Katmai Oncology Group
Anchorage, Alaska, United States, 99508
4
Providence Alaska Medical Center
Anchorage, Alaska, United States, 99508